100 % Datengenauigkeit
Wissenschaftlicher Support rund um die Uhr
0 % Toleranz bei der Produktqualität
Lagerstandorte
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Vorbehaltlich Verfügbarkeit
Dokumentation
Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.
70459-07-3Norfloxacin EP Impurity K
● Auf Lager
| Katalog-Nr.:: | VL3030001 |
|---|---|
| CAS-Nr.:: | 70459-07-3 |
| Summenformel:: | C15H16FN3O3 |
| Molare Masse:: | 305.3 g/mol |
Zusätzliche Informationen zu CAS 70459-07-3
Parent drug
NorfloxacinIUPAC-Name
6-Fluoro-1, 4-dihydro-1-methyl-4-Oxo-7-(1-piperazinyl)-3-quinolinecarboxylic AcidPharmakopöe-Synonyme
Norfloxacin Related Compound KOther Synonyms
6-fluoro-1-methyl-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; Norfloxacin N-Methyl AnalogSMILES
O=C(C1=CN(C)C2=C(C=C(F)C(N3CCNCC3)=C2)C1=O)OInchl
InChI=1S/C15H16FN3O3/c1-18-8-10(15(21)22)14(20)9-6-11(16)13(7-12(9)18)19-4-2-17-3-5-19/h6-8,17H,2-5H2,1H3,(H,21,22)Beschreibung
Norfloxacin EP Impurity K (CAS No: 70459-07-3) or Norfloxacin N-Methyl Analog is an impurity present in Norfloxacin which is one of the new 4-quinolone antibacterial agents, a fluorinated piperazinyl-substituted congener of nalidixic acid, it demonstrates a much wider in vitro antibacterial spectrum and greater potency than the parent compound.References
Nageswara Rao, R., and V. Nagaraju. “Separation and Determination of Synthetic Impurities of Norfloxacin by Reversed-Phase High Performance Liquid Chromatography.†Journal of Pharmaceutical and Biomedical Analysis, vol. 34, no. 5, Mar. 2004, pp. 1049–56, https://doi.org/10.1016/j.jpba.2003.11.009.?Angebot anfordern
„*“ zeigt erforderliche Felder an
Other products related to Norfloxacin impurities
Verunreinigungsstruktur
Name der Muttersubstanz
CAS-Nr.:
Name der Verunreinigung
Katalog-Nr.:
